DK1973545T3 - Bicykliske heteroarylforbindelser - Google Patents
Bicykliske heteroarylforbindelserInfo
- Publication number
- DK1973545T3 DK1973545T3 DK06845939.5T DK06845939T DK1973545T3 DK 1973545 T3 DK1973545 T3 DK 1973545T3 DK 06845939 T DK06845939 T DK 06845939T DK 1973545 T3 DK1973545 T3 DK 1973545T3
- Authority
- DK
- Denmark
- Prior art keywords
- bicyclic heteroaryl
- heteroaryl compounds
- compounds
- bicyclic
- heteroaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75396205P | 2005-12-23 | 2005-12-23 | |
US75400005P | 2005-12-23 | 2005-12-23 | |
US75608906P | 2006-01-03 | 2006-01-03 | |
US79847206P | 2006-05-08 | 2006-05-08 | |
US83319106P | 2006-07-25 | 2006-07-25 | |
PCT/US2006/048758 WO2007075869A2 (en) | 2005-12-23 | 2006-12-22 | Bicyclic heteroaryl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1973545T3 true DK1973545T3 (da) | 2013-02-25 |
Family
ID=38218600
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06845939.5T DK1973545T3 (da) | 2005-12-23 | 2006-12-22 | Bicykliske heteroarylforbindelser |
DK12169710.6T DK2495016T3 (da) | 2005-12-23 | 2006-12-22 | Bicykliske heteroarylforbindelser |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12169710.6T DK2495016T3 (da) | 2005-12-23 | 2006-12-22 | Bicykliske heteroarylforbindelser |
Country Status (20)
Country | Link |
---|---|
US (9) | US8114874B2 (da) |
EP (4) | EP3417912B1 (da) |
JP (3) | JP5200939B2 (da) |
KR (1) | KR101436303B1 (da) |
CN (1) | CN103044432B (da) |
AU (1) | AU2006331673B2 (da) |
CA (1) | CA2634923C (da) |
CY (3) | CY1113907T1 (da) |
DK (2) | DK1973545T3 (da) |
EA (2) | EA027573B1 (da) |
ES (2) | ES2761180T3 (da) |
HU (2) | HUE047422T2 (da) |
IL (2) | IL191938A (da) |
LT (1) | LT2495016T (da) |
LU (1) | LU92327I2 (da) |
MX (2) | MX2008008152A (da) |
PL (2) | PL1973545T3 (da) |
PT (2) | PT2495016T (da) |
SI (1) | SI2495016T1 (da) |
WO (1) | WO2007075869A2 (da) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1940843A4 (en) | 2005-08-11 | 2010-09-15 | Ariad Pharma Inc | UNSATURATED HETEROCYCLIC DERIVATIVES |
MX2008008152A (es) * | 2005-12-23 | 2008-09-12 | Ariad Pharma Inc | Compuestos heterociclicos biciclicos. |
KR101441365B1 (ko) * | 2006-05-08 | 2014-09-18 | 어리어드 파마슈티칼스, 인코포레이티드 | 모노시클릭 헤테로아릴 화합물 |
JP5273037B2 (ja) | 2006-05-08 | 2013-08-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | アセチレン性ヘテロアリール化合物 |
TW200817410A (en) * | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
US8143410B2 (en) | 2006-11-16 | 2012-03-27 | Allergan, Inc. | Kinase inhibitors |
WO2008061236A2 (en) | 2006-11-16 | 2008-05-22 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
US8558002B2 (en) | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
MY188338A (en) * | 2006-11-22 | 2021-11-30 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
EP2300455B1 (en) | 2008-05-21 | 2017-07-19 | Incyte Holdings Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
FR2933981A1 (fr) * | 2008-07-18 | 2010-01-22 | Sanofi Aventis | NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET |
JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
WO2010056311A1 (en) | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
MX2012005023A (es) | 2009-10-30 | 2012-06-19 | Ariad Pharma Inc | Metodos y composiciones para tratar cancer. |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EA025304B1 (ru) * | 2010-02-03 | 2016-12-30 | Инсайт Холдингс Корпорейшн | ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ |
CN101885722B (zh) * | 2010-07-01 | 2013-07-24 | 中国科学院广州生物医药与健康研究院 | 杂环炔苯类化合物及其药用组合物和应用 |
US8846671B2 (en) | 2010-07-01 | 2014-09-30 | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof |
MX336051B (es) * | 2011-01-21 | 2016-01-07 | Sun Pharma Advanced Res Co Ltd | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. |
WO2012127030A1 (en) * | 2011-03-23 | 2012-09-27 | Proteosys Ag | Arylpiperazines as neuroprotective agents |
BR112013024171A2 (pt) * | 2011-04-07 | 2016-12-13 | Ariad Pharma Inc | método para o tratamento e prevenção de uma condição neurodegenerativa |
AU2012363094A1 (en) * | 2011-04-07 | 2013-09-19 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating Parkinson's disease |
RU2477723C2 (ru) * | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
EP2841062A4 (en) * | 2012-04-25 | 2015-11-25 | Ariad Pharma Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY RAF KINASE |
US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
WO2013170774A1 (zh) * | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
US8859553B2 (en) * | 2012-07-30 | 2014-10-14 | Astar Biotech Llc | Protein kinase inhibitors |
US20150291594A1 (en) * | 2012-08-14 | 2015-10-15 | Concert Pharmaceuticals, Inc. | Deuterated Ponatinib |
CN103664787B (zh) * | 2012-09-17 | 2015-09-09 | 南京圣和药业股份有限公司 | 炔杂芳环化合物及其应用 |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途 |
CN103848829B (zh) | 2012-11-28 | 2017-04-12 | 南京圣和药业股份有限公司 | 杂芳基炔烃化合物及其应用 |
CA2815506C (en) | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
US20140343282A1 (en) | 2013-05-16 | 2014-11-20 | Apicore, Llc | Processes for making ponatinib and intermediates thereof |
WO2015001098A1 (en) * | 2013-07-04 | 2015-01-08 | Sandoz Ag | Crystalline forms of ponatinib hydrochloride |
CN104341416B (zh) * | 2013-07-31 | 2017-03-29 | 南京圣和药业股份有限公司 | 蛋白酪氨酸激酶抑制剂及其应用 |
GB2518873A (en) * | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
CN104650086A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 盐酸帕纳替尼化合物 |
WO2015085973A1 (en) | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt |
WO2015085972A1 (en) | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE |
WO2015085971A1 (en) | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide |
CN104496940B (zh) * | 2014-01-06 | 2017-03-15 | 广东东阳光药业有限公司 | 一种制备bcr‑abl抑制剂中间体的方法 |
GB2522226A (en) * | 2014-01-17 | 2015-07-22 | Agency Science Tech & Res | Heteroaryl alkyne derivatives and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
KR20170016921A (ko) | 2014-06-06 | 2017-02-14 | 낫코 파마 리미티드 | 항증식성 화합물로서 1h-1, 8-나프티리딘-2-원 |
CN105272930B (zh) | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN105837575B (zh) * | 2015-01-13 | 2019-01-15 | 四川大学 | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 |
AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CN106167491A (zh) * | 2015-05-19 | 2016-11-30 | 重庆大学 | 一种有效抑制肺癌转移的化合物及其应用 |
US9988389B2 (en) | 2015-06-11 | 2018-06-05 | Apicore Us Llc | Processes for making ponatinib and intermediates thereof |
CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
CA3016161A1 (en) | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
CN109641893B (zh) * | 2016-06-20 | 2021-07-20 | 大邱庆北尖端医疗产业振兴财团 | 新的咪唑并吡啶衍生物及其制备方法和用途 |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
US10221184B2 (en) | 2017-01-20 | 2019-03-05 | Apicore Us Llc | Polymorphs of ponatinib hydrochloride |
RU2768887C2 (ru) * | 2017-03-15 | 2022-03-25 | Сан Фарма Эдвансд Рисёч Компани Лимитед | Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты |
WO2018167802A1 (en) * | 2017-03-15 | 2018-09-20 | Sun Pharma Advanced Research Company Limited | Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide |
CA3067271A1 (en) | 2017-06-20 | 2018-12-27 | Apotex Inc. | Crystalline forms of ponatinib hydrochloride |
JP7024960B2 (ja) * | 2017-10-04 | 2022-02-24 | 国立大学法人京都大学 | Bcr-Ablタンパク質イメージング用分子プローブ |
EP3781568A1 (en) | 2018-06-22 | 2021-02-24 | Johnson Matthey Public Limited Company | Form of ponatinib |
EP3795571B1 (en) * | 2018-07-02 | 2024-05-08 | Shenzhen TargetRx, Inc. | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity |
EP3808746B1 (en) | 2018-07-17 | 2023-08-02 | Shenzhen TargetRx, Inc. | N-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]ethynyl]phenyl]-benzamide derivatives and related compounds as protein kinase inhibitors for the treatment of cancer |
CN113227094A (zh) * | 2018-09-12 | 2021-08-06 | 普渡研究基金会 | 作为激酶抑制剂的炔基烟酰胺化合物 |
WO2020079652A1 (en) | 2018-10-17 | 2020-04-23 | Insilico Medicine Hong Kong Limited | Kinase inhibitors |
CN113677346A (zh) | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
WO2020214999A1 (en) * | 2019-04-17 | 2020-10-22 | Emory University | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases |
WO2020223235A1 (en) | 2019-04-29 | 2020-11-05 | Incyte Corporation | Mini-tablet dosage forms of ponatinib |
KR102205619B1 (ko) | 2019-06-12 | 2021-01-21 | 한국과학기술연구원 | 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
CN111004240B (zh) * | 2019-12-13 | 2020-12-01 | 山东铂源药业有限公司 | 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法 |
US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2021228983A1 (en) | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer |
EP4175957A1 (en) * | 2020-06-24 | 2023-05-10 | Purdue Research Foundation | 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors |
WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
US20220289756A1 (en) * | 2021-03-11 | 2022-09-15 | Wai Kit Pang | Compounds and compositions as inhibitors of protein kinases |
CN112778207A (zh) * | 2021-03-19 | 2021-05-11 | 海南鑫开源医药科技有限公司 | 一种盐酸尼洛替尼原料药杂质及其制备方法 |
BR112023021215A2 (pt) * | 2021-04-13 | 2023-12-19 | Shenzhen Newdel Biotech Co Ltd | Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos |
WO2022225972A1 (en) * | 2021-04-19 | 2022-10-27 | Oregon Health & Science University | Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US5099057A (en) | 1987-10-19 | 1992-03-24 | The Dow Chemical Company | Process for the preparation of ar-amino-para-arenediols |
US5099067A (en) | 1988-08-05 | 1992-03-24 | Northwestern University | Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
DE69106902T2 (de) | 1990-03-01 | 1995-07-06 | Takeda Chemical Industries Ltd | Imidazopyridazine, ihre Herstellung und Verwendung. |
ATE208778T1 (de) | 1995-05-09 | 2001-11-15 | Basf Ag | Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung |
GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
ES2240202T3 (es) | 1999-11-08 | 2005-10-16 | Schering Corporation | Procedimiento de preparacion de n-(4-hidroxifenil)-n'-(4'-aminofenil)piperazina. |
AU2001236471A1 (en) | 2000-01-18 | 2001-07-31 | Neurogen Corporation | Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors |
HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
DE10019714A1 (de) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
EP1301511A2 (en) | 2000-07-14 | 2003-04-16 | Bristol-Myers Squibb Pharma Company | IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
DE10117184A1 (de) | 2001-04-05 | 2002-10-17 | Gruenenthal Gmbh | Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen |
DE10117183A1 (de) | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
US6933290B2 (en) | 2001-05-30 | 2005-08-23 | Novartis Ag | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives |
WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
IL159811A0 (en) * | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
EP1431299B1 (en) | 2001-09-04 | 2007-05-23 | Sumitomo Chemical Company, Limited | IMIDAZO(1,2-a)PYRIMIDINES AND FUNGICIDE COMPOSITIONS CONTAINING THE SAME |
JP2003103658A (ja) * | 2001-10-01 | 2003-04-09 | Oshio Sangyo Kk | 注出口付き包装体の製造装置・製造方法並びに該製造方法の実施に使用する袋保持ユニット |
ES2485841T3 (es) | 2002-02-01 | 2014-08-14 | Ariad Pharmaceuticals, Inc | Compuestos que contienen fósforo y usos de los mismos |
AU2003221731B2 (en) | 2002-04-19 | 2010-04-15 | Cgi Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof |
EA008622B1 (ru) * | 2002-06-05 | 2007-06-29 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Ингибиторы ассоциированной с иммунитетом протеинкиназы |
EP1541575B1 (en) | 2002-07-29 | 2010-03-03 | Sumitomo Chemical Company, Limited | Novel process for producing imidazo(1,2-b)pyridazine derivative |
ES2384558T3 (es) | 2002-09-11 | 2012-07-06 | Becton Dickinson And Company | Monitorización de glucosa en sangre incluyendo la presentación visual conveniente de promedios y valores de mediciones |
DE10246890A1 (de) | 2002-10-08 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine |
DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
AR041992A1 (es) * | 2002-11-06 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla |
GB0230089D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
ATE398452T1 (de) | 2003-09-24 | 2008-07-15 | Wyeth Corp | 6-aryl-7-halo-imidazoä1,2-aüpyrimidine als mittel gegen krebs |
US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
WO2005051366A2 (en) | 2003-11-28 | 2005-06-09 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
NZ546782A (en) | 2003-12-05 | 2010-04-30 | Biovitrum Ab | Improved synthesis of 2-substituted adenosines such as spongosine |
ATE402705T1 (de) * | 2003-12-24 | 2008-08-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
EP1737463B1 (en) * | 2003-12-24 | 2008-12-03 | AstraZeneca AB | Pyrimidines with tie2 (tek) activity |
PE20051089A1 (es) | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
AU2005231980B2 (en) * | 2004-04-07 | 2011-09-08 | Merck Serono Sa | 1,1'-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors |
DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
BRPI0511834A (pt) * | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
CN101180299B (zh) * | 2005-03-23 | 2010-12-15 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物 |
JP2008534565A (ja) | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Tie2阻害活性のあるアミノピリミジン誘導体 |
EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
EP1940843A4 (en) | 2005-08-11 | 2010-09-15 | Ariad Pharma Inc | UNSATURATED HETEROCYCLIC DERIVATIVES |
SI1973545T1 (sl) * | 2005-12-23 | 2013-04-30 | Ariad Pharmaceuticals, Inc. | Spojine bicikličnega heteroarila |
MX2008008152A (es) * | 2005-12-23 | 2008-09-12 | Ariad Pharma Inc | Compuestos heterociclicos biciclicos. |
JP5273037B2 (ja) * | 2006-05-08 | 2013-08-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | アセチレン性ヘテロアリール化合物 |
KR101441365B1 (ko) * | 2006-05-08 | 2014-09-18 | 어리어드 파마슈티칼스, 인코포레이티드 | 모노시클릭 헤테로아릴 화합물 |
EP2107054A1 (en) | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
US20100273772A1 (en) | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
US8461851B2 (en) | 2009-06-08 | 2013-06-11 | University Of Hawaii | Systems for transverse electromagnetic mode in-situ soil testing |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
MX2012005023A (es) | 2009-10-30 | 2012-06-19 | Ariad Pharma Inc | Metodos y composiciones para tratar cancer. |
BR112013024171A2 (pt) | 2011-04-07 | 2016-12-13 | Ariad Pharma Inc | método para o tratamento e prevenção de uma condição neurodegenerativa |
JP5300939B2 (ja) * | 2011-08-25 | 2013-09-25 | 安田工業株式会社 | 仕上加工用工具を用いた加工方法 |
CA2815506C (en) | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
-
2006
- 2006-12-22 MX MX2008008152A patent/MX2008008152A/es active IP Right Grant
- 2006-12-22 EP EP18183366.6A patent/EP3417912B1/en active Active
- 2006-12-22 EP EP20184076.6A patent/EP3747441A1/en active Pending
- 2006-12-22 ES ES12169710T patent/ES2761180T3/es active Active
- 2006-12-22 EP EP06845939A patent/EP1973545B1/en active Active
- 2006-12-22 PT PT121697106T patent/PT2495016T/pt unknown
- 2006-12-22 LT LTEP12169710.6T patent/LT2495016T/lt unknown
- 2006-12-22 WO PCT/US2006/048758 patent/WO2007075869A2/en active Application Filing
- 2006-12-22 PL PL06845939T patent/PL1973545T3/pl unknown
- 2006-12-22 CN CN201210427822.9A patent/CN103044432B/zh active Active
- 2006-12-22 DK DK06845939.5T patent/DK1973545T3/da active
- 2006-12-22 EP EP12169710.6A patent/EP2495016B1/en active Active
- 2006-12-22 ES ES06845939T patent/ES2403206T3/es active Active
- 2006-12-22 SI SI200632359T patent/SI2495016T1/sl unknown
- 2006-12-22 AU AU2006331673A patent/AU2006331673B2/en active Active
- 2006-12-22 MX MX2013004842A patent/MX343042B/es unknown
- 2006-12-22 PT PT68459395T patent/PT1973545E/pt unknown
- 2006-12-22 EA EA200870116A patent/EA027573B1/ru not_active IP Right Cessation
- 2006-12-22 DK DK12169710.6T patent/DK2495016T3/da active
- 2006-12-22 CA CA2634923A patent/CA2634923C/en active Active
- 2006-12-22 US US11/644,849 patent/US8114874B2/en active Active
- 2006-12-22 KR KR1020087018122A patent/KR101436303B1/ko active Protection Beyond IP Right Term
- 2006-12-22 JP JP2008547538A patent/JP5200939B2/ja active Active
- 2006-12-22 EA EA201790678A patent/EA034598B1/ru unknown
- 2006-12-22 HU HUE12169710A patent/HUE047422T2/hu unknown
- 2006-12-22 PL PL12169710T patent/PL2495016T3/pl unknown
-
2008
- 2008-06-04 IL IL191938A patent/IL191938A/en active IP Right Grant
-
2012
- 2012-01-25 US US13/357,745 patent/US8470851B2/en active Active
- 2012-12-05 JP JP2012266072A patent/JP5790629B2/ja active Active
-
2013
- 2013-01-31 CY CY20131100091T patent/CY1113907T1/el unknown
- 2013-03-13 US US13/801,619 patent/US8778942B2/en active Active
- 2013-03-13 US US13/801,116 patent/US9029533B2/en active Active
- 2013-12-05 LU LU92327C patent/LU92327I2/fr unknown
- 2013-12-06 CY CY2013044C patent/CY2013044I2/el unknown
- 2013-12-20 HU HUS1300078C patent/HUS1300078I1/hu unknown
-
2014
- 2014-06-04 US US14/296,016 patent/US9278971B2/en active Active
-
2015
- 2015-04-14 JP JP2015082840A patent/JP6604739B2/ja active Active
- 2015-06-16 IL IL239445A patent/IL239445A/en active IP Right Grant
-
2016
- 2016-01-21 US US15/003,537 patent/US20160368917A1/en not_active Abandoned
-
2018
- 2018-08-06 US US16/055,362 patent/US20190031656A1/en not_active Abandoned
-
2019
- 2019-12-11 CY CY20191101304T patent/CY1122646T1/el unknown
- 2019-12-20 US US16/722,881 patent/US20200231588A1/en not_active Abandoned
-
2021
- 2021-10-12 US US17/498,796 patent/US20220081440A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2013044I1 (el) | Δικυκλικες ετεροαρυλ ενωσεις | |
CY2013047I2 (el) | Ενωσεις διαρυλυδαντοϊνης | |
SI1973545T1 (sl) | Spojine bicikličnega heteroarila | |
ATE443056T1 (de) | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen | |
DK1937650T3 (da) | Heterocykliske forbindelser | |
DE602006018341D1 (de) | Antihypercholesterinämische verbindungen | |
DK1957492T3 (da) | Substituerede bicykliske pyrimidonderivater | |
DK1943406T3 (da) | Byggeelement | |
ATE404546T1 (de) | Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen | |
DE502006001027D1 (de) | Cyanuraten | |
DE602006018950D1 (de) | N-dihydroxyalkyl-substitutierte 2-oxoimidazolderivate | |
ATE384719T1 (de) | Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen | |
FR2884161B1 (fr) | Architecture de machine-outil | |
SE0402103D0 (sv) | Novel compounds | |
FI20050832A (fi) | Uudet yhdisteet | |
SE0500057D0 (sv) | Chemical compounds | |
ATE473232T1 (de) | Carbapenemdverbindung | |
TH0501004012B (th) | สารประกอบ | |
SE0402391D0 (sv) | Novelheterocyclic compounds | |
DOP2004000959A (es) | Compuestos | |
SE0403054D0 (sv) | Novel compounds | |
SE0402068D0 (sv) | Novel compounds | |
SE0402069D0 (sv) | Novel compounds | |
SE0401885D0 (sv) | Novel compounds | |
SE0401348D0 (sv) | Novel compounds |